Literature DB >> 21844656

Metabolomic analysis reveals novel isoniazid metabolites and hydrazones in human urine.

Feng Li1, Yan Miao, Lirong Zhang, Sarah Ann Neuenswander, Justin T Douglas, Xiaochao Ma.   

Abstract

Isoniazid (INH) is a first-line drug for tuberculosis control; the side effects of INH are thought to be associated with its metabolism, and this study was designed to globally characterize isoniazid metabolism. Metabolomic strategies were used to profile isoniazid metabolism in humans. Eight known and seven novel INH metabolites and hydrazones were identified in human urine. The novel products included two hydroxylated INH metabolites and five hydrazones. The two novel metabolites were determined as 2-oxo-1,2-dihydro-pyridine-4-carbohydrazide and isoniazid N-oxide. Five novel hydrazones were produced by condensation of isoniazid with keto acids that are intermediates in the metabolism of essential amino acids, namely, leucine and/or isoleucine, lysine, tyrosine, tryptophan, and phenylalanine. This study enhances our knowledge of isoniazid metabolism and disposition and may offer new avenues for investigating INH-induced toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844656     DOI: 10.2133/dmpk.DMPK-11-RG-055

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  16 in total

1.  The Isoniazid Metabolites Hydrazine and Pyridoxal Isonicotinoyl Hydrazone Modulate Heme Biosynthesis.

Authors:  Christopher Trent Brewer; Lei Yang; Anne Edwards; Yan Lu; Jonathan Low; Jing Wu; Richard E Lee; Taosheng Chen
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

2.  Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.

Authors:  Kevin R MacKenzie; Mingkun Zhao; Mercedes Barzi; Jin Wang; Karl-Dimiter Bissig; Mirjana Maletic-Savatic; Sung Yun Jung; Feng Li
Journal:  Eur J Pharm Sci       Date:  2020-07-23       Impact factor: 4.384

3.  Role of CYP3A in isoniazid metabolism in vivo.

Authors:  Ke Liu; Feng Li; Jie Lu; Zhiwei Gao; Curtis D Klaassen; Xiaochao Ma
Journal:  Drug Metab Pharmacokinet       Date:  2013-10-29       Impact factor: 3.614

4.  CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid.

Authors:  Jie Cheng; Kristopher W Krausz; Feng Li; Xiaochao Ma; Frank J Gonzalez
Journal:  Toxicol Appl Pharmacol       Date:  2012-11-08       Impact factor: 4.219

5.  A High Dose of Isoniazid Disturbs Endobiotic Homeostasis in Mouse Liver.

Authors:  Feng Li; Pengcheng Wang; Ke Liu; Mariana G Tarrago; Jie Lu; Eduardo N Chini; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2016-08-16       Impact factor: 3.922

6.  Cell Type-Specific Roles of CD38 in the Interactions of Isoniazid with NAD+ in the Liver.

Authors:  Junjie Zhu; Jie Lu; Hung-Chun Tung; Ke Liu; Jianhua Li; Denis M Grant; Wen Xie; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2020-10-05       Impact factor: 3.922

7.  Deficiency of N-acetyltransferase increases the interactions of isoniazid with endobiotics in mouse liver.

Authors:  Pengcheng Wang; Amina I Shehu; Jie Lu; Rujuta H Joshi; Raman Venkataramanan; Kim S Sugamori; Denis M Grant; Xiao-Bo Zhong; Xiaochao Ma
Journal:  Biochem Pharmacol       Date:  2017-09-06       Impact factor: 5.858

8.  Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.

Authors:  Mrinal Kumar Das; Rakesh Arya; Sanjita Debnath; Rahul Debnath; Anindita Lodh; Subasa Chandra Bishwal; Anjan Das; Ranjan Kumar Nanda
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

9.  Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury.

Authors:  Yifan Bao; Xiaochao Ma; Theodore P Rasmussen; Xiao-Bo Zhong
Journal:  Curr Pharmacol Rep       Date:  2018-03-15

10.  Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites.

Authors:  Tyler B Hughes; Na Le Dang; Ayush Kumar; Noah R Flynn; S Joshua Swamidass
Journal:  J Chem Inf Model       Date:  2020-09-16       Impact factor: 4.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.